Patents Assigned to United States of America Department of Health and Human Services
-
Publication number: 20210322415Abstract: Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy.Type: ApplicationFiled: February 14, 2017Publication date: October 21, 2021Applicants: ASTRAZENECA AB, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Simon BARRY, Jane KENDREW, Tony HO, Stephen Robert WEDGE, Susan Percy IVY, Elise KOHN, Jung-Min LEE
-
Patent number: 10981977Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.Type: GrantFiled: June 17, 2020Date of Patent: April 20, 2021Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myoung-Hwa Lee
-
Patent number: 10335460Abstract: Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15R?”) to patients in order to enhance IL-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. In another specific aspect, the dose escalation regimens are useful for eradicating or reducing HIV in HIV-infected patients.Type: GrantFiled: July 28, 2015Date of Patent: July 2, 2019Assignees: NOVARTIS AG, The United States of America Department of Health and Human ServicesInventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John N. Vournakis
-
Patent number: 10266488Abstract: Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells.Type: GrantFiled: October 10, 2014Date of Patent: April 23, 2019Assignees: Eastern Virginia Medical School, The Regents of the University of California Santa Cruz, The United States of America Department of Health and Human Services, Thomas Jefferson UniversityInventors: David J. Maloney, Diane K. Luci, Ajit Jadhav, Theodore Holman, Jerry L. Nadler, Michael Holinstat, David Taylor-Fishwick, Anton Simeonov, Adam Yasgar, Steven McKenzie
-
Patent number: 9259452Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.Type: GrantFiled: January 6, 2015Date of Patent: February 16, 2016Assignees: Gelgene Corporation, The United States of America Department of Health and Human ServicesInventors: William McCulloch, Richard L. Piekarz, Susan E. Bates
-
Patent number: 7858928Abstract: Embodiments of the invention include methods and devices for the analysis of proteins utilizing a gold coated nanoporous alumina surface for dual ionization mode mass spectrometric analysis using desorption electrospray ionization (DESI) and laser desorption ionization (LDI). Combined use of DESI and LDI gives increased sequence coverage in peptide mixture analysis from a single sample preparation.Type: GrantFiled: September 20, 2007Date of Patent: December 28, 2010Assignee: The United States of America Department of Health and Human ServicesInventor: Daniel R. Knapp
-
Publication number: 20090092557Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viralType: ApplicationFiled: May 27, 2005Publication date: April 9, 2009Applicant: Government of the United States of America Department of Health and Human ServicesInventors: Michael R. Boyd, Toshiyuki Mori, Barry R. O'Keefe
-
Publication number: 20090029930Abstract: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.Type: ApplicationFiled: December 11, 2006Publication date: January 29, 2009Applicants: Utah, University of, Research Foundation, Johns Hopkins University, Baylor College of Medicine, United States of America Department of Health and Human ServicesInventors: Rando Allikmets, Kent L. Anderson, Michael Dean, Mark Leppert, Richard A. Lewis, Yixin Li, James R. Lupski, Jeremy Nathans, Amir Rattner, Noah F. Shroyer, Nanda Singh, Philip Smallwood, Hui Sun
-
Patent number: 7402400Abstract: The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.Type: GrantFiled: August 10, 2001Date of Patent: July 22, 2008Assignees: Regents of the University of California, The United States of America Department of Health and Human ServicesInventors: Charles S. Zuker, Nicholas J. P. Ryba, Gregory A. Nelson, Mark A. Hoon, Jayaram Chandrashekar, Yifeng Zhang
-
Patent number: 7250097Abstract: An apparatus and method for the sequential electroelution of biomolecules is described, the apparatus comprising a separation medium having an outlet, and a collector having at least a first receptacle and a second receptacle that can be sequentially brought into contact with the outlet of the separation medium by translating the first receptacle and the second receptacle in relation to the outlet of the separation medium, and the method comprising the steps of receiving a first substantially separated molecule in the first receptacle and translating the first receptacle and the second receptacle such that the second receptacle is brought into in contact with the outlet of the separation medium, receiving a second substantially separated molecule in the second receptacle, and repeating said steps to sequentially receive a desired number of substantially separated molecules.Type: GrantFiled: July 9, 2004Date of Patent: July 31, 2007Assignee: The United States of America, Department of Health and Human ServicesInventors: József Antal, Zsuzsanna Buzás, Andreas Chrambach
-
Publication number: 20060057556Abstract: Contiguous capillaries useful for separating and electrospraying a fluid comprising analyte and electrolyte are provided. The contiguous capillaries have spray tips at one end of the capillaries and electrically conductive portions in proximity to the spray tips. Methods for making the contiguous capillaries and their use as electrospray sources are also disclosed. Apparatus and methods for conveying analyte ions from the capillaries into analytical instruments, such as a mass spectrometer, are also disclosed. The disclosed contiguous capillaries may be used to carryout electrophoresis separation and electrospray ionization of analytes. Methods for obtaining the mass spectra of macromolecular analytes at concentrations lower than previously possibly are provided using the apparatus and procedures described herein.Type: ApplicationFiled: October 20, 2003Publication date: March 16, 2006Applicant: The Government of the United States of America Department of Health and Human ServicesInventors: George Janini, Haleem Issaq, Timothy Veenstra, Thomas Conrads, Kenneth Wilkens
-
Publication number: 20040204395Abstract: The present invention relates to water-soluble drugs, compositions containing same, and, in particular, a water-soluble analogue of geldanamycin. This invention also relates to a method of producing water-soluble analogues of water-insoluble drugs through derivatization and conjugation with a polar moiety via a thiol ether bond with a heterobifunctional linking molecule.Type: ApplicationFiled: May 3, 2004Publication date: October 14, 2004Applicant: Government of the United States of America, Department of Health and Human ServicesInventors: David K. Ho, Raya Mandler, Ada Belinda Alvarado-Lindner, Kaye B. Dillah Upadhyay, David J. Newman
-
Publication number: 20030148506Abstract: A method of producing an adeno-associated virus (AAV) in an insect cell comprising (i) providing at least one insect cell-compatible vector comprising a first nucleotide sequence comprising at least one AAV ITR nucleotide sequence, a second nucleotide sequence containing an open reading frame encoding AAV VP1, VP2, and VP3 capsid proteins, a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence, and a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence, (ii) introducing the at least one insect cell-compatible vector into an insect cell, and (iii) maintaining the insect cell under conditions such that AAV is produced. Also provided are recombinant AAV made in accordance with the method, insect cell-compatible vectors, and insect cells comprising nucleotide sequences for production of AAV in an insect cell.Type: ApplicationFiled: August 13, 2002Publication date: August 7, 2003Applicant: The Government of the United States of America, Department of Health and Human ServicesInventors: Robert M. Kotin, Masashi Urabe, Chuan-Tian Ding
-
Publication number: 20030059771Abstract: The present invention relates to Ras-family proteins and tumor suppressor genes. Specifically, the present invention provides the Ras-related tumor suppressor gene and protein Rig, as well as means for the regulation of cell growth.Type: ApplicationFiled: June 4, 2001Publication date: March 27, 2003Applicant: THE UNITED STATES OF AMERICA, Department of Health and Human ServicesInventors: Geoff J. Clark, Chad A. Ellis, Michelle Vos
-
Publication number: 20020151886Abstract: Disclosed are methods and devices for occluding the lumen of a hollow organ by delivering radiofrequency energy to the inner wall of a hollow organ. The disclosure includes radiofrequency electrodes that expand, in a deployed condition, to contact the walls of the organ. In some embodiments, the electrodes substantially conform to the inner wall to enhance therapeutic contact. Methods are also disclosed for using these electrodes to totally or partially occlude a lumen, or remove or reduce a total or partial occlusion of a lumen.Type: ApplicationFiled: December 6, 2001Publication date: October 17, 2002Applicant: The Government of the United States of America, Department of the Health and Human ServicesInventor: Bradford J. Wood
-
Publication number: 20020123049Abstract: A recombinant plasmid and an RNA sequence expressed by said plasmid are described. The RNA sequence hybridize specifically with human c-fes mRNA.Type: ApplicationFiled: May 15, 2001Publication date: September 5, 2002Applicant: The United States of America, Department of Health and Human ServicesInventors: Robert I. Glazer, Thomas E. Smithgall, Gang Yu
-
Publication number: 20020077308Abstract: The present invention provides a method of treating or preventing the inflammatory response of an inflammatory bowel disease in a subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the inflammatory response of the inflammatory bowel disease.Type: ApplicationFiled: March 19, 2001Publication date: June 20, 2002Applicant: The Government of The United States of America, Department of Health and Human ServicesInventors: Warren Strober, Ivan Fuss, Markus Neurath, Atsushi Kitani
-
Publication number: 20020013299Abstract: The present invention provides AGT inactivating compounds such as substituted O6-benzylguanines of the formula 1Type: ApplicationFiled: August 14, 2001Publication date: January 31, 2002Applicant: The Government of the United States of America, Department of Health and Human ServicesInventors: Robert C. Moschel, Anthony E. Pegg, M. Eileen Dolan, Mi-Young Chae
-
Publication number: 20020002144Abstract: The present invention provides a method of producing a bisubstrate inhibitor in a cell, comprising introducing into the cell an alkylating derivative of an acetyl acceptor substrate for an acetyltransferase present in the cell. Further provided is a method of inhibiting the activity of an acetyltransferase in a cell, comprising introducing into the cell an alkylating derivative of an acetyl acceptor substrate for an acetyltransferase present in the cell under conditions whereby a bisubstrate inhibitor will be produced, thereby inhibiting the activity of the acetyltransferase in the cell.Type: ApplicationFiled: July 20, 2001Publication date: January 3, 2002Applicant: The Government of the United States of America, Department of Health & Human ServicesInventors: David C. Klein, M. A.A. Namboodiri, Joan L. Weller, Jeffrey A. Kowalak, Anthony K. Ho
-
Publication number: 20010053958Abstract: The present invention is directed to an improved method for detecting a genetic marker in a biological sample comprising contacting the biological sample with a nucleic acid probe linked to a detectable moiety, whereby the detectable moiety can be detected by the presence of a chromogenic dye associated with the detectable moiety, obtaining a spectral image of the biological sample using brightfield microscopy, and detecting the presence of the chromogenic dye, thereby detecting the genetic marker in the biological sample.Type: ApplicationFiled: June 29, 2001Publication date: December 20, 2001Applicant: The Govenment of the United States of America, Department of Health & Human ServicesInventors: Thomas Ried, Merryn V.E. Macville, Anton H.N. Hopman